Clinical Characteristics and Outcomes of Acute Myeloid Leukemia Patients Harboring Triple Mutations and the Potential Prognostic Value of .

IntroductionNucleophosmin 1 (), FMS-like tyrosine kinase 3-internal tandem duplication (), and de novo methyl transferase 3 A () triple-mutated acute myeloid leukemia (AML) represents a distinct entity with poor outcomes.MethodsWe explored the gene mutation spectrum and clinical characteristics of 165 AML patients retrospectively, particularly comparing patients with triple-mutations and those without.ResultsOur results demonstrated significantly elevated white blood cell counts ( < 0.001), bone marrow blast percentages ( = 0.037), and platelet counts ( = 0.007) in the triple-mutated cohort (6.7%) compared to the non-triple-mutated patients. Furthermore, all triple-mutated cases were classified as the M4/M5 subtype of the French-American-British classification ( = 0.017). Although no significant difference in complete remission rates was observed between the groups after initial treatment, the median overall survival for triple-mutated AML patients was only 4 months. Using the Gene Expression Omnibus (GEO) database and bioinformatics, we compared AML and AML. A total of 246 AML patients from the GEO dataset were included to evaluate the expression profiles of differentially expressed genes. The guanine nucleotide-binding protein subunit γ 4 () was differentially expressed between AML and AML, which had the most adjacent nodes among hub genes. The prognostic value of was further validated in AML patient samples through qRT-PCR.ConclusionClinical validation indicated a substantial downregulation of in AML compared to AML patients. Thus, may play a role in the low survival rate of AML patients, offering novel insights into the prognosis, therapeutic targets, and prognostic evaluation of AML.